Kalorama: Orthopedic biomaterials market to experience double-digit growth
Medical market research firm Kalorama predicted double-digit growth in the orthopedic biomaterials market through 2016, and estimated that the market represented 14 percent of 2010 global orthopedics sales, or about $5.8 billion, according to its recently published report “Orthopedic Biomaterials, the World Market.”
Orthopedic biomaterials are organic or synthetic products that are implanted into or near a bone fracture to facilitate healing. Used in several types of orthopedic surgery, the products include surface coatings, bone cements, bone defect fillers and fracture fixation plates, according to Kalorama.
Advances in gene therapy and stem cell research are key drivers for the growth, the firm noted.
“Advances in gene therapy and stem cell research may offer new solutions for state-of-the-art treatments for these musculoskeletal conditions,” noted Bruce Carlson, publisher of Kalorama Information. “Many researchers believe that genetically engineered stem cells will have a significant impact on the fields of regenerative medicine and tissues engineering as a powerful cell source that will work in conjunction with biomaterials to treat tissue and bone loss.”
Information gathered in Kalorama’s market outlook was collected using primary and secondary sources, telephone interviews and email correspondence with industry officials, consultants, health care providers, surgeons, research institutes and government personnel. Coverage includes historical revenues from 2006 to 2010 and market predictions through 2016.
Orthopedic biomaterials are organic or synthetic products that are implanted into or near a bone fracture to facilitate healing. Used in several types of orthopedic surgery, the products include surface coatings, bone cements, bone defect fillers and fracture fixation plates, according to Kalorama.
Advances in gene therapy and stem cell research are key drivers for the growth, the firm noted.
“Advances in gene therapy and stem cell research may offer new solutions for state-of-the-art treatments for these musculoskeletal conditions,” noted Bruce Carlson, publisher of Kalorama Information. “Many researchers believe that genetically engineered stem cells will have a significant impact on the fields of regenerative medicine and tissues engineering as a powerful cell source that will work in conjunction with biomaterials to treat tissue and bone loss.”
Information gathered in Kalorama’s market outlook was collected using primary and secondary sources, telephone interviews and email correspondence with industry officials, consultants, health care providers, surgeons, research institutes and government personnel. Coverage includes historical revenues from 2006 to 2010 and market predictions through 2016.